Pembrolizumab-Belzutifan Combination Improves Disease-Free Survival in Renal Cell Carcinoma

A groundbreaking study published in the New England Journal of Medicine demonstrates that the combination of pembrolizumab and belzutifan significantly improves disease-free survival in patients with clear-cell renal cell carcinoma. This immunotherapy and targeted therapy combination represents an important therapeutic advance for kidney cancer patients. The research shows promising results in preventing disease progression and recurrence after treatment. For renal cell carcinoma patients, this combination offers a new treatment option that may improve long-term outcomes and quality of life.

Originally published on
Medical Xpress
Read full article(opens in new tab)Fetched: July 7, 2026 at 10:12 AM



